| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 07/15/2009 | EP1741430B1 Remedy for psychoneurotic diseases |
| 07/15/2009 | EP1740587A4 Selective antagonists of a-2a- adenosine receptors |
| 07/15/2009 | EP1706106B1 Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances |
| 07/15/2009 | EP1519746B1 Use of digoxin immune fab for the regulation of sodium/potassium atpase activity in preeclamptic and eclamptic patients |
| 07/15/2009 | EP1517989B1 Method for the diagnosing of sphingolipid metabolism |
| 07/15/2009 | EP1403279B1 Protein polymer having unfold activity on higher-order structure of protein |
| 07/15/2009 | EP1379514B1 5-membered heterocycles, preparation and application thereof as medicaments |
| 07/15/2009 | EP1370268B1 Methods for treating stress disorders using glucocorticoid receptor-specific antagonists |
| 07/15/2009 | EP1268802B1 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 07/15/2009 | EP1261335B1 Combination of n-acetyl-l-tryptophan and magnesium sulphate for the treatment of brain, spinal and nerve injury |
| 07/15/2009 | EP1141015B1 Insulin-like growth factor (igf) i mutant variants |
| 07/15/2009 | CN101484210A Treatment of pain disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthalenamine and its formamide |
| 07/15/2009 | CN101481405A Somatostatin-dopamine chimeric analogs |
| 07/15/2009 | CN101481359A Cyclic protein tyrosine kinase inhibitors |
| 07/15/2009 | CN100513570C Regulation effect of conjugated frame transport protein ABC1 |
| 07/15/2009 | CN100513406C Novel quinuclidine derivatives and their use |
| 07/15/2009 | CN100513397C Pyridine n-oxide compounds as phosphodiesterase 4 inhibitors |
| 07/15/2009 | CN100512832C Medication for treating ache |
| 07/15/2009 | CN100512824C Medication for treating headache |
| 07/15/2009 | CN100512809C Compounds and methods of treating transplant rejection |
| 07/15/2009 | CN100512806C Therapeutic patch with polysiloxane matrix comprising capsaicin |
| 07/14/2009 | USRE40851 3,3-diphenylpropylamines, their use and preparation |
| 07/14/2009 | US7560569 (2S,4S)-1-[[(4-carbamoylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile, for treating type II diabetes; increase glucagon-like peptide activity |
| 07/14/2009 | US7560562 1-methyl-3-ethoxymethyl-4-(3,4-dichlorophenyl)-piperidine; nervous system disorders |
| 07/14/2009 | US7560548 antiinflammatory agent N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}cyclopropane carboxamide; bronchitis, asthma, chronic obstructive pulmonary disease and rhinitis |
| 07/14/2009 | US7560480 Alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments |
| 07/14/2009 | US7560473 Amine derivative with potassium channel regulatory function, its preparation and use |
| 07/14/2009 | US7560470 Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands |
| 07/14/2009 | US7560464 (5-Methoxy-2-pyridin-2-yl-pyrimidin-4-yl)-(5-pyrrolidin-1-yl-pyridin-2-yl)-amine; SK channel modulators (SK=small conductance calcium activated potassium channels); antiepileptic agents; seizures; learning enhancement; cognition activators; mood/psychotic disorders; antidepressants; Parkinson's disease |
| 07/14/2009 | US7560459 Substituted sulfamate anticonvulsant derivatives |
| 07/14/2009 | US7560458 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 07/14/2009 | US7560453 Labeling and idagnostic imaging of histamine H3 receptor; therapy for Alzheimer's disease, nervous system disorders, antiepileptic agents, neuropathic pain, Parkinson's disease, multiple sclerosis, strokes, sleep disorders, schizophrenia, attention deficit disorders, drug abruse, antiallergens |
| 07/14/2009 | US7560449 Methods and therapeutic combinations for the treatment of demyelination |
| 07/14/2009 | US7560442 For prophylaxis and therapy of diabetes mellitus Type I and Type II, inflammation, cancer, necrosis, gastric ulcers, neurodegenerative diseases (Alzheimer's disease, Parkinson's disease), neuropathic diseases, neuropathic pain and polyneuropathy |
| 07/14/2009 | US7560247 Nucleic acids encoding anti-IL-12 antibodies, and methods of production |
| 07/14/2009 | CA2532818C (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists |
| 07/14/2009 | CA2403321C Amide compounds and use thereof |
| 07/14/2009 | CA2382302C A nucleic acid and encoding polypeptide for use in inhibiting tumor angiogenesis |
| 07/14/2009 | CA2360776C Highly purified ethyl epa and other epa derivatives for psychiatric and neurological disorders |
| 07/14/2009 | CA2338090C Nutritional and therapeutic compositions of 3-hydroxyacids for increasing blood ketone bodies |
| 07/14/2009 | CA2335285C Bicyclic piperidine and piperazine compounds having 5-ht6 receptor affinity |
| 07/14/2009 | CA2262972C Compositions of plant carbohydrates as dietary supplements |
| 07/14/2009 | CA2183543C Sexual steroid-containing transdermal therapeutic systems |
| 07/09/2009 | WO2009086277A1 Tetrasubstituted benzenes |
| 07/09/2009 | WO2009086202A2 Methods for treating neuropsychiatric conditions |
| 07/09/2009 | WO2009085988A1 Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7- dihydro-5h-pyrrolo[3,4-b]pyrazine |
| 07/09/2009 | WO2009085972A1 Maleate, besylate, and l-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5h-pyrrolo[3,4-b]pyrazine |
| 07/09/2009 | WO2009085945A1 Benzothiazole and benzoxazole derivatives and methods of use |
| 07/09/2009 | WO2009085200A2 Anti-amyloid antibodies and uses thereof |
| 07/09/2009 | WO2009084970A1 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use |
| 07/09/2009 | WO2009084695A1 2-aminoquinazoline derivative |
| 07/09/2009 | WO2009084653A1 Method for screening of cell-protecting agent |
| 07/09/2009 | WO2009084232A1 Sugar chain-related gene and use thereof |
| 07/09/2009 | WO2009083930A1 Caspase-8 inhibitors and uses thereof |
| 07/09/2009 | WO2009083929A1 Caspase-1 inhibitors and uses thereof |
| 07/09/2009 | WO2009083871A1 Combination between an isothiocyanate and levodopa for parkinson's disease treatment |
| 07/09/2009 | WO2009083794A1 Pharmaceutical compositions containing an inclusion complex formed by disulfiram and a cyclodextrin, which can be used in the treatment of alcohol and cocaine dependence |
| 07/09/2009 | WO2009083793A1 Inclusion complex formed by disulfiram and a cyclodextrin, which can be used in the treatment of alcohol and cocaine dependence |
| 07/09/2009 | WO2009083738A2 Rna delivery vehicles |
| 07/09/2009 | WO2009083612A2 Flavonoid as means for the prophylaxis and treatment of neurodegenerative and other protein folding-aberration diseases |
| 07/09/2009 | WO2009083581A1 Carboxamide compounds and their use as calpain inhibitors |
| 07/09/2009 | WO2009083559A1 Substituted oxindole-derivatives and the use thereof for the treatment of vasopressin-dependent illnesses |
| 07/09/2009 | WO2009083526A1 Novel compounds |
| 07/09/2009 | WO2009083115A1 Pharmaceuticals and the production and use thereof in the treatment of painful neuropathies |
| 07/09/2009 | WO2009061924A3 Aldh-2 inhibitors in the treatment of psychiatric disorders |
| 07/09/2009 | WO2009043524A3 Use of a peptide as therapeutic agent |
| 07/09/2009 | WO2009042200A9 Solid forms comprising 3-(2,5-dimethyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| 07/09/2009 | WO2009033814A3 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 07/09/2009 | WO2009033806A3 Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| 07/09/2009 | WO2009033764A3 Use of a peptide as a therapeutic agent |
| 07/09/2009 | WO2009033749A3 Use of thymopentin as a therapeutic agent |
| 07/09/2009 | WO2009033748A3 Use of osteostatin, alone or in combination with thymopentin, as a therapeutic agent |
| 07/09/2009 | WO2009008991A3 Dna-pkcs modulates energy regulation and brain function |
| 07/09/2009 | WO2008151833A3 Compounds for the modulation of huntingtin aggregation, methods and means for identifying such compounds |
| 07/09/2009 | WO2008147864A3 Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions |
| 07/09/2009 | WO2008041140A8 Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| 07/09/2009 | US20090178148 Compositions and methods for modifying the content of polyunsaturated fatty acids in mammalian cells |
| 07/09/2009 | US20090176883 TRPA1 Antagonists |
| 07/09/2009 | US20090176878 Genetic polymorphisms and substance dependence |
| 07/09/2009 | US20090176855 Treatment of bipolar disorders and associated symptoms |
| 07/09/2009 | US20090176853 Adamantane derivatives |
| 07/09/2009 | US20090176851 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 |
| 07/09/2009 | US20090176850 Novel 2-Amino-Imidazole-4-One Compounds And Their Use In The Manufacture Of A Medicament To Be Used In The Treatment Of Cognitive Impairment, Alzheimer's Disease, Neurodegeneration And Dementia |
| 07/09/2009 | US20090176845 adrenergic receptor agonists such as (8-Methoxy-1,2,3,4-tetrahydro-naphthalen-2-yl)-propyl-pyridin-4-ylmethyl-amine, used as analgesics, decongestants, antidepressants and anxiolytic agents or for the treatment of vision defects, neurodegenerative diseases, diarrhea, attention deficit disorder, psychoses |
| 07/09/2009 | US20090176843 Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
| 07/09/2009 | US20090176841 Novel 6-5 system bicyclic heterocyclic derivative and its pharmaceutical utility |
| 07/09/2009 | US20090176840 Use of galr3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods |
| 07/09/2009 | US20090176838 Cyclourea Compounds as Calcium Channel Blockers |
| 07/09/2009 | US20090176837 Compounds with activity at retinoic acid receptors |
| 07/09/2009 | US20090176836 3-{[(3-amino-3-benzyltetrahydrofuran-2-yl)oxy]methyl}-N-[(1R)-1-(4-fluorophenyl)ethyl]-5-[(methylsulfonyl)(propyl)amino]benzamide, used for preventing the formation of insoluble amyloid proteins |
| 07/09/2009 | US20090176829 Bicyclic heteroaryl compounds as pde10 inhibitors |
| 07/09/2009 | US20090176828 treating pain with minimal cardiovascular and/or sedatory activity side effects;hypertension, depression, glaucoma, elevated intraocular pressure, ischemic neuropathies, optic neuropathy, diabetic retinopathy, stroke, withdrawal symptoms, obsessive compulsive disorder, obesity, diarrhea, nasal congestion |
| 07/09/2009 | US20090176814 Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains |
| 07/09/2009 | US20090176808 combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist |
| 07/09/2009 | US20090176807 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 07/09/2009 | US20090176806 protein kinase C or glycogen synthase kinase-3-beta inhibitors such as 3-(2-chlorophenyl)-4-[1-(3-hydroxypropyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]-1H-pyrrole-2,5-dione, used for treating cardiovascular, skin, nervous system disorders and immunological disorders, diabetes, inflammatory diseases and cancer |
| 07/09/2009 | US20090176800 In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia |
| 07/09/2009 | US20090176799 Phosphodiesterase 4 inhibitors |
| 07/09/2009 | US20090176796 Trpv1 antagonists including amide substituent and uses thereof |
| 07/09/2009 | US20090176794 1h-indol-1-yl-urea compounds |